Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20458161 | 1.00 | NOTUM (0.53) | NOTUMALOX12THRBKMT2AMAPT | |
| SCHEMBL5702089 | 0.83 | NOTUM (0.49) | NOTUMKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL5702158 | 0.83 | NOTUM (0.49) | NOTUMKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL13015198 | 0.82 | GFER (0.41) | NOTUMALOX12THRBKMT2AMAPT | |
| SCHEMBL2121764 | 0.82 | NOTUM (0.53) | NOTUMKMT2AMAPTALDH1A1HPGD | |
| SCHEMBL2121761 | 0.82 | NOTUM (0.53) | NOTUMKMT2AMAPTALDH1A1HPGD | |
| SCHEMBL7035832 | 0.82 | GFER (0.41) | NOTUMALOX12THRBKMT2AMAPT | |
| SCHEMBL21660768 | 0.80 | SCN9A (0.43) | NOTUMKMT2AHRH3CA1CA2 | |
| SCHEMBL20141514 | 0.80 | NOTUM (0.48) | NOTUMALOX12THRBKMT2AMAPT | |
| SCHEMBL5394683 | 0.79 | NOTUM (0.43) | NOTUMALOX12THRBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831834-A1 | BORATE OF AZETIDINE DERIVATIVE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210163507-A1 | BORATE OF AZETIDINE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-06-03 | — | — | US | disclosed |
| US-11014943-B2 | Azetidine derivative | CHIA TAI TIANQING PHARMACEUTICAL GROUP GO., LTD. (CN) | 2021-05-25 | — | — | US | disclosed |
| US-20200115392-A1 | AZETIDINE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| WO-2020025037-A1 | BORATE OF AZETIDINE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2020-02-06 | — | — | WO | disclosed |
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | NOTUM 2816/4885ALOX12 668/4885THRB 1041/4885 |
| US-11014943-B2 | Azetidine derivative | BCL9, MCL1, BCL9L | NOTUM 2946/4885ALOX12 2204/4885THRB 2841/4885 |
| US-20200115392-A1 | AZETIDINE DERIVATIVE | BCL9, MCL1, BCL9L | NOTUM 2946/4885ALOX12 2204/4885THRB 2841/4885 |
| US-20210163507-A1 | BORATE OF AZETIDINE DERIVATIVE | BCL9, BCL6, BCL6B | NOTUM 2959/4885ALOX12 2277/4885THRB 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.